TIDMSNG

RNS Number : 4361R

Synairgen plc

06 July 2022

Synairgen plc

('Synairgen' or the 'Company')

Grant of Options

Southampton, UK - 6 July 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that on 5 July 2022 the Board of Synairgen granted options ('Options') over 6,407,130 ordinary shares of one pence each in the capital of the Company ('Ordinary Shares') at an exercise price of one pence per Ordinary Share. The Options represent in aggregate 3.18 per cent. of the Company's issued share capital.

Following this grant, Synairgen has 14,891,262 options in issue, representing 7.39 per cent. of the Company's issued share capital.

Certain Options were issued to Directors of the Company and Persons Discharging Managerial Responsibilities ('PDMR'):

 
                                                                          Percentage 
                         Options                                          holding of 
                        issued 5       Total   Ordinary       Total    fully diluted 
                       July 2022     options     shares    interest    share capital 
 Directors 
                      ----------  ----------  ---------  ----------  --------------- 
 Richard Marsden(1)      534,482   2,813,995    995,771   3,809,766            1.76% 
                      ----------  ----------  ---------  ----------  --------------- 
 Dr. Phillip 
  Monk                   387,931   2,034,254    423,934   2,458,188            1.14% 
                      ----------  ----------  ---------  ----------  --------------- 
 John Ward               387,931   2,160,889    734,092   2,894,981            1.34% 
                      ----------  ----------  ---------  ----------  --------------- 
 PDMRs 
                      ----------  ----------  ---------  ----------  --------------- 
 Jody Brookes            515,000     979,166          -     979,166            0.45% 
                      ----------  ----------  ---------  ----------  --------------- 
 Brooke Clarke(2)        515,000     628,636      8,520     637,156            0.29% 
                      ----------  ----------  ---------  ----------  --------------- 
 Richard Francis         515,000     628,636          -     628,636            0.29% 
                      ----------  ----------  ---------  ----------  --------------- 
 Richard Hennings        515,000     757,568          -     757,568            0.35% 
                      ----------  ----------  ---------  ----------  --------------- 
 Gareth Walters          515,000     635,779          -     635,779            0.29% 
                      ----------  ----------  ---------  ----------  --------------- 
 
   1.   Richard Marsden's shareholding includes 184,821 shares held in his pension plan. 
   2.   Brooke Clarke's shareholding is held by her spouse. 

The Options are issued under the Company's Long Term Incentive Plan and are exercisable up to 4 July 2032, subject to the achievement of appropriate performance criteria which match the criteria for the 2021 award as set out on page 24 of the 2021 annual report.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No. 596/2014 ('MAR')

For further enquiries, please contact:

Synairgen plc

Brooke Clarke, Head of Communications

Media@synairgen.com

Tel: + 44 (0) 23 8051 2800

finnCap (NOMAD and Joint Broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Sunil de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield, Duncan Monteith

Tel: + 44 (0) 20 7260 1000

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott, Namrata Taak, Lucy Featherstone

cscsynairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5700

MKC STRATEGIES, LLC (US Media Relations)

Mary Conway

MConway@MKCStrategies.com

Tel: +1 516-606-6545

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of severe viral lung infections, including COVID-19, as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. SNG001 has been granted Fast Track status from the US Food and Drug Administration (FDA). Founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com .

 
1.  Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated 
     with them ('PCA') 
a)  Name                                         Richard Marsden 
2.  Reason for notification 
a)  Position / status                            Chief Executive Officer 
b)  Initial notification / amendment             Initial Notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                         Synairgen plc 
b)  LEI                                          213800IMMTOPPDF8HD24 
4.  Details of the transaction(s): 
a)  Description of the financial instrument      Options over ordinary shares of 1p each 
 
     Identification code 
                                                  GB00B0381Z20 
b)  Nature of the transaction                    Award of Options under the Company's share plans 
c)  Price(s) and volume(s)                       534,482 Options awarded 
d)  Aggregated information                       n/a 
     Aggregated volume Price 
e)  Date of the transaction                      5 July 2022 
f)  Place of the transaction                     Outside a trading venue 
 
 
1.  Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated 
     with them ('PCA') 
a)  Name                                         Dr Phillip Monk 
2.  Reason for notification 
a)  Position / status                            Chief Scientific Officer 
b)  Initial notification / amendment             Initial Notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                         Synairgen plc 
b)  LEI                                          213800IMMTOPPDF8HD24 
4.  Details of the transaction(s): 
a)  Description of the financial instrument      Options over ordinary shares of 1p each 
 
     Identification code 
                                                  GB00B0381Z20 
b)  Nature of the transaction                    Award of Options under the Company's share plans 
c)  Price(s) and volume(s)                       387,931 Options awarded 
d)  Aggregated information                       n/a 
     Aggregated volume Price 
e)  Date of the transaction                      5 July 2022 
f)  Place of the transaction                     Outside a trading venue 
 
 
1.  Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated 
     with them ('PCA') 
a)  Name                                         John Ward 
2.  Reason for notification 
a)  Position / status                            Chief Financial Officer 
b)  Initial notification / amendment             Initial Notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                         Synairgen plc 
b)  LEI                                          213800IMMTOPPDF8HD24 
4.  Details of the transaction(s): 
a)  Description of the financial instrument      Options over ordinary shares of 1p each 
     Identification code 
 
                                                  GB00B0381Z20 
b)  Nature of the transaction                    Award of Options under the Company's share plans 
c)  Price(s) and volume(s)                        387,931 Options awarded 
d)  Aggregated information                       n/a 
     Aggregated volume Price 
e)  Date of the transaction                      5 July 2022 
f)  Place of the transaction                     Outside a trading venue 
 
 
1.  Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated 
     with them ('PCA') 
a)  Name                                         Jody Brookes 
2.  Reason for notification 
a)  Position / status                            Head of Clinical Operations 
b)  Initial notification / amendment             Initial Notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                         Synairgen plc 
b)  LEI                                          213800IMMTOPPDF8HD24 
4.  Details of the transaction(s): 
a)  Description of the financial instrument      Options over ordinary shares of 1p each 
 
     Identification code 
                                                  GB00B0381Z20 
b)  Nature of the transaction                    Award of Options under the Company's share plans 
c)  Price(s) and volume(s)                        515,000 Options awarded 
d)  Aggregated information                       n/a 
     Aggregated volume Price 
e)  Date of the transaction                      5 July 2022 
f)  Place of the transaction                     Outside a trading venue 
 
 
1.  Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated 
     with them ('PCA') 
a)  Name                                         Brooke Clarke 
2.  Reason for notification 
a)  Position / status                            Head of Communications 
b)  Initial notification / amendment             Initial Notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                         Synairgen plc 
b)  LEI                                          213800IMMTOPPDF8HD24 
4.  Details of the transaction(s): 
a)  Description of the financial instrument      Options over ordinary shares of 1p each 
 
     Identification code 
                                                  GB00B0381Z20 
b)  Nature of the transaction                    Award of Options under the Company's share plans 
c)  Price(s) and volume(s)                        515,000 Options awarded 
d)  Aggregated information                       n/a 
     Aggregated volume Price 
e)  Date of the transaction                      5 July 2022 
f)  Place of the transaction                     Outside a trading venue 
 
 
1.  Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated 
     with them ('PCA') 
a)  Name                                         Richard Francis 
2.  Reason for notification 
a)  Position / status                            Head of CMC 
b)  Initial notification / amendment             Initial Notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                         Synairgen plc 
b)  LEI                                          213800IMMTOPPDF8HD24 
4.  Details of the transaction(s): 
a)  Description of the financial instrument      Options over ordinary shares of 1p each 
 
     Identification code 
                                                  GB00B0381Z20 
b)  Nature of the transaction                    Award of Options under the Company's share plans 
c)  Price(s) and volume(s)                        515,000 Options awarded 
d)  Aggregated information                       n/a 
     Aggregated volume Price 
e)  Date of the transaction                      5 July 2022 
f)  Place of the transaction                     Outside a trading venue 
 
 
1.  Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated 
     with them ('PCA') 
a)  Name                                         Richard Hennings 
2.  Reason for notification 
a)  Position / status                            Chief Commercial Officer 
b)  Initial notification / amendment             Initial Notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                         Synairgen plc 
b)  LEI                                          213800IMMTOPPDF8HD24 
4.  Details of the transaction(s): 
a)  Description of the financial instrument      Options over ordinary shares of 1p each 
 
     Identification code 
                                                  GB00B0381Z20 
b)  Nature of the transaction                    Award of Options under the Company's share plans 
c)  Price(s) and volume(s)                        515,000 Options awarded 
d)  Aggregated information                       n/a 
     Aggregated volume Price 
e)  Date of the transaction                      5 July 2022 
f)  Place of the transaction                     Outside a trading venue 
 
 
1.  Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated 
     with them ('PCA') 
a)  Name                                         Gareth Walters 
2.  Reason for notification 
a)  Position / status                            Chief Regulatory Officer 
b)  Initial notification / amendment             Initial Notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                         Synairgen plc 
b)  LEI                                          213800IMMTOPPDF8HD24 
4.  Details of the transaction(s): 
a)  Description of the financial instrument      Options over ordinary shares of 1p each 
 
     Identification code 
                                                  GB00B0381Z20 
b)  Nature of the transaction                    Award of Options under the Company's share plans 
c)  Price(s) and volume(s)                        515,000 Options awarded 
d)  Aggregated information                       n/a 
     Aggregated volume Price 
e)  Date of the transaction                      5 July 2022 
f)  Place of the transaction                     Outside a trading venue 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEAEXSEAPAEAA

(END) Dow Jones Newswires

July 06, 2022 02:00 ET (06:00 GMT)

Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Sep 2022 a Oct 2022 Haga Click aquí para más Gráficas Synairgen.
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Oct 2021 a Oct 2022 Haga Click aquí para más Gráficas Synairgen.